Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.16 is 143% above its 5-year average of 0.07, around the middle of its 5-year range (-0.25–0.54).
As of the fiscal period ended Tuesday, June 30, 2026. 342.18% above its 12-month average of -0.07.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.16.
DEBT TO EQUITY RATIO
0.16
DEBT TO EQUITY RATIO AVG TTM
-0.07
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.07
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+342.18%
CURRENT VS 3Y AVG
+9485.20%
CURRENT VS 5Y AVG
+143.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 516 covered companies
CURRENT VS SECTOR MEDIAN
+18.33%
vs the sector median at left
Market Cap
$82.35M
Debt to Equity Ratio
N/A
TTM Avg
0.33
3Y Avg
0.19
5Y Avg
0.13
Market Cap
$80.25M
Debt to Equity Ratio
1.43
TTM Avg
0.85
3Y Avg
0.55
5Y Avg
0.41
Market Cap
$81.83M
Debt to Equity Ratio
0.25
TTM Avg
0.08
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$83.89M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$84.98M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.76M
Debt to Equity Ratio
1.83
TTM Avg
0.28
3Y Avg
0.24
5Y Avg
0.19
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENSAR Inc (LNSR) | $81.98M | 0.16 | -0.07 | 0.00 | 0.07 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $82.35M | N/A | 0.33 | 0.19 | 0.13 |
| Pulmonx Corporation (LUNG)vs › | $80.25M | 1.43 | 0.85 | 0.55 | 0.41 |
| Citius Oncology, Inc. (CTOR)vs › | $81.83M | 0.25 | 0.08 | 0.04 | 0.04 |
| MediciNova, Inc. (MNOV)vs › | $83.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.89M | 0.02 | 0.02 | 0.03 | 0.03 |
| Conexeu Sciences Inc. (CNXU)vs › | $84.98M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | 1.83 | 0.28 | 0.24 | 0.19 |
| Humacyte, Inc. (HUMA)vs › | $84.03M | 2.12 | 20.86 | 8.51 | 5.27 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.20M | 0.02 | 0.03 | 0.04 | 0.03 |
Debt/Equity
0.16
Current Ratio
2.39
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.16 |
| 2026-03-31 | 0.10 |
| 2025-12-31 | -0.11 |
| 2025-09-30 | -0.24 |
| 2025-06-30 | -0.25 |
| 2025-03-31 | -0.11 |
| 2024-12-31 | 0.54 |
| 2024-09-30 | 0.08 |
| 2024-06-30 | 0.05 |
| 2024-03-31 | 0.07 |
| 2023-12-31 | 0.07 |
| 2023-09-30 | 0.07 |
| 2023-06-30 | 0.08 |
| 2023-03-31 | 0.07 |
| 2022-12-31 | 0.07 |
| 2022-09-30 | 0.07 |
| 2022-06-30 | 0.07 |
| 2022-03-31 | 0.06 |
| 2021-12-31 | 0.06 |
| 2021-09-30 | 0.05 |
| 2021-06-30 | 0.05 |
| 2021-03-31 | 0.05 |
| 2020-12-31 | 0.06 |
| 2020-09-30 | 0.05 |
| 2020-06-30 | -1.87 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | -0.67 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
